GlassScriptPhysician profile
Rukmini Konatalapalli
NPI 1053500074
$6,658.39
in general payments reported to CMS, 2019-2025
33 companies · $1,561 in 2025
The $1,561 reported for 2025 was more than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,948 · 2020: $795 · 2021: $381 · 2022: $825 · 2023: $346 · 2024: $804 · 2025: $1,561.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,684 · Education: $26.15.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,684.12 |
| Education | $26.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,167.47 | 2019-2025 | |
| Scilex Pharmaceuticals INC. | $944.14 | 2019-2024 | Ztlido |
| Amgen INC. | $699.68 | 2019-2025 | Krystexxa, Tavneos |
| Novartis Pharmaceuticals Corporation | $462.81 | 2019-2025 | |
| Janssen Biotech, INC. | $401.37 | 2019-2025 | Tremfya |
| Ani Pharmaceuticals, INC. | $324.84 | 2025 | Purified Cortrophin Gel, Sovuna |
| Horizon Therapeutics Plc | $310.59 | 2019-2023 | Krystexxa |
| Pfizer INC. | $275.24 | 2019-2025 | |
| Mallinckrodt Hospital Products INC. | $251.93 | 2020-2025 | Acthar |
| Ucb, INC. | $250.56 | 2019-2025 | Bimzelx, Cimzia |
| Mallinckrodt Enterprises LLC | $183.93 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $178.18 | 2022-2025 | Saphnelo, Flumist Quadrivalent |
| Glaxosmithkline, LLC. | $158.28 | 2019-2025 | Benlysta |
| E.R. Squibb & Sons, L.L.C. | $152.59 | 2019-2024 | Orencia |
| Aurinia Pharma U.S., INC. | $101.09 | 2022-2025 | Lupkynis |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $94.73 | 2019-2025 | Actemra |
| Radius Health, INC. | $82.00 | 2019-2020 | |
| Lilly USA, LLC | $76.51 | 2019-2023 | Taltz |
| Alexion Pharmaceuticals, INC. | $72.83 | 2024-2025 | Strensiq |
| Merck Sharp & Dohme LLC | $70.32 | 2019-2020 | |
| Regeneron Healthcare Solutions, INC. | $65.93 | 2019 | |
| Fresenius Kabi USA, LLC | $64.42 | 2023-2025 | Idacio |
| Sandoz INC. | $58.80 | 2023-2024 | Hyrimoz |
| Depuy Synthes Sales INC. | $28.10 | 2019 | |
| Celltrion USA INC. | $26.15 | 2023 | Yuflyma |
| Boehringer Ingelheim Pharmaceuticals, INC. | $25.75 | 2020 | |
| Saluda Medical Americas, INC. | $23.75 | 2025 | Evoke |
| Celgene Corporation | $21.48 | 2019 | |
| Hikma Pharmaceuticals USA | $20.08 | 2019 | |
| Pacira Pharmaceuticals Incorporated | $17.87 | 2023 | Zilretta, Iovera |
| Pacira Therapeutics, INC. | $17.47 | 2019 | |
| Medtronic, INC. | $17.12 | 2024 | Intellis Adaptivestim |
| Genzyme Corporation | $12.38 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rukmini Konatalapalli listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.